KA
ABEO icon

Kovack Advisors’s Abeona Therapeutics ABEO Stock Holding History

Kovack Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.9K Hold
10,560
– – ﹤0.01% 1056
2026
Q1 		$48.4K Buy
+10,560
New +$52.8K ﹤0.01% 995

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kovack Advisors's ABEO Position: Q2 2026 in Review

Kovack Advisors held its Abeona Therapeutics (ABEO) position steady in Q2 2026 at 10,560 shares worth $63.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1056.

Kovack Advisors first reported a position in ABEO in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Kovack Advisors held 10,560 shares of Abeona Therapeutics worth $63.9K as of Q2 2026.
  • Kovack Advisors left its Abeona Therapeutics share count unchanged in Q2 2026.
  • Abeona Therapeutics made up ﹤0.01% of Kovack Advisors's portfolio in Q2 2026, its #1056 holding.
  • Kovack Advisors first reported a position in Abeona Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.